AZ’s MedImmune Buys Spirogen To Boost Oncology ADC Capability

AstraZeneca agreed to pay $200 million upfront and $240 million in predefined milestones for Spirogen to enhance its early oncology pipeline with linked tumor-targeted antibody drug conjugates. The company simultaneously announced a collaboration with ADC Therapeutics to jointly develop ADCs.